Targeting higher Hb levels with ESA therapy is associated with an increased risk of stroke, hypertension, and vascular access thrombosis, as well as a possible increased risk for death, serious cardiovascular events, and end-stage renal disease [34]. The gene discussed is GSTM1; the disease is stroke disorder.